STOCK TITAN

Eagle Pharmaceuticals Inc - EGRX STOCK NEWS

Welcome to our dedicated news page for Eagle Pharmaceuticals (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eagle Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eagle Pharmaceuticals's position in the market.

Rhea-AI Summary
Eagle Pharmaceuticals, Inc. provided an update on its bendamustine intellectual property portfolio, including the affirmation by the United States Court of Appeals for the Federal Circuit of the decision that 505(b)(2) drug applications referencing BELRAPZO® did not infringe Eagle’s previously issued ‘483 patent. The company also announced the granting of U.S. Patent Nos. 11844783 and 11872214 covering Eagle’s innovative bendamustine liquid formulations, listed in the Orange Book for both BENDEKA® and BELRAPZO. Eagle filed lawsuits asserting that 505(b)(2) products referencing BELRAPZO marketed by other companies infringe the newly issued patents and requesting damages. The company's Interim Principal Executive Officer and Interim Executive Chairman, Michael Graves, stated that they will continue to take appropriate steps to enforce their rights related to the newly issued patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is under investigation by Lifshitz Law PLLC for possible securities laws violations and/or breaches of fiduciary duties. Allegations include slower-than-anticipated pull-through from a wholesale customer, overstated revenue, ineffective internal controls, and misleading positive statements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that its abstract, a post-hoc analysis of two multicenter, placebo-controlled, Phase III studies evaluating amisulpride (a selective dopamine D2/D3 antagonist) as an antiemetic in patients with established postoperative nausea and vomiting, has been selected for a poster presentation at the 77th PGA (PostGraduate Assembly in Anesthesiology). Barhemsys® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV. A single 10 mg dose of intravenous amisulpride significantly reduced patients’ nausea across multiple measures, including significant nausea, use of rescue medication, and evolution of nausea over time. The adverse event profile was comparable between the placebo and 10 mg amisulpride arms. The abstract details pooled data on nausea-related outcomes from two Phase III trials, showing that the proportion of patients with PONV experiencing substantial nausea in these studies was statistically significantly lower in the amisulpride 10 mg group than in the placebo group. Eagle Pharmaceuticals believes Barhemsys presents an opportunity for a much-needed therapeutic option for these patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) received a notice from Nasdaq regarding non-compliance with listing requirements due to the delayed filing of financial reports. The company has until January 26, 2024, to submit a plan to regain compliance, with a possible extension until May 7, 2024. Failure to comply may lead to delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.98%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announces the retirement of CEO and Founder Scott Tarriff, with Chairman Michael Graves serving as Interim Executive Chairman. The company will initiate a search for a new CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.98%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a delay in the release of its third quarter 2023 results and investor conference call, citing the need for more time to review potential adjustments relating to the reporting of sales of PEMFEXY®. The company also expects to revise its previously disclosed 2023 full year guidance downward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.36%
Tags
earnings
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) to release Q3 2023 financial results on November 9, 2023. President and CEO Scott Tarriff and CFO Brian Cahill to host conference call. Webcast available for replay. Dial-in and webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences earnings
-
Rhea-AI Summary
Eagle Pharmaceuticals has been granted a new patent for its pemetrexed formulations, which includes its FDA-approved commercial formulation of PEMFEXY. The patent will expire in 2036 and is expected to strengthen the company's patent portfolio. Sales of PEMFEXY remain strong, with a 24% market share in the commercial pemetrexed market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
-
Rhea-AI Summary
Eagle Pharmaceuticals announces that Centers for Medicare & Medicaid Services has established a unique billing code and granted transitional pass-through payment status for Barhemsys injection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
Rhea-AI Summary
Eagle Pharmaceuticals announces first prize at ISAP Annual Meeting for pharmacokinetic analysis of remimazolam in pediatric patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
Eagle Pharmaceuticals Inc

Nasdaq:EGRX

EGRX Rankings

EGRX Stock Data

64.92M
10.39M
12.02%
86.36%
8.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Woodcliff Lake

About EGRX

specialty pharmaceutical company